Equity strategist + Co-PM Global Equities [Bernard Holdings]. Objective view on the directional bias of markets. Technical expertise bridges the complex relationships between value drivers, capital flows and price action. Partners are represented over the cross-section of financial markets, from speculators, hedgers, long-term traders and the public. Research covers investment securities and futures & options markets. Shoot me a message to talk trade ideas or portfolio construction. Disclaimer:All research ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|----------------- ...

Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2024 Earnings Conference Call December 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2025 Earnings Call. At this time, all participants are in a listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded. I will now tu ...

Exhibit 99.1 Creating Greater Certainty In the Fight Against Cancer NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 million Hackensack, NJ – December 11, 2024 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 3 ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|-------------------- ...

Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2025 Earnings Conference Call September 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2025 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator In ...

Exhibit 99.1 Creating Greater Certainty In the Fight Against Cancer NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million Hackensack, NJ – September 11, 2024 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, ...

Champions Oncology, Inc. (NASDAQ:CSBR) Q4 2024 Earnings Conference Call July 18, 2024 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matthew Hewitt - Craig-Hallum I will now turn the conference over to your host, Dr. Ronnie Morris, CEO of Champions Oncology. You may begin. Good afternoon. I am Ronnie Morris, CEO of Champions Oncology. Joining me today is David Miller, our Chief Financial Officer. Thank you for joining us for our quarterly earnings call. T ...

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds and 101.INS* iXBRL Instance Document. 101.SCH* iXBRL Taxonomy Extension Sche ...

Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2024 Earnings Conference Call March 12, 2024 4:30 PM ET Operator Good afternoon. I am Ronnie Morris, CEO of Champions Oncology. Joining me today is David Miller, our Chief Financial Officer. Thank you for joining us for our quarterly earnings call. Our business development strategy is taking hold, which will contribute to our already strong bookings, which are the fundamental foundation for building long-term success. As these higher bookings convert to revenue over ...